Trevi Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDTrevi Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings contraction of 2% provides fundamental context to the price action. Investors should exercise caution due to high volatility (62% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.25 | -1.37% | BELOW |
| 50 SMA | $12.79 | +9.88% | ABOVE |
| 100 SMA | $12.08 | +16.30% | ABOVE |
| 150 SMA | $11.83 | +18.81% | ABOVE |
| 200 SMA | $10.83 | +29.70% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TRVI in an uptrend right now?
TRVI has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, TRVI is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is TRVI overbought or oversold?
TRVI's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is TRVI outperforming the market?
TRVI has a Relative Strength (RS) Rating of 84 out of 99. Yes, TRVI is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is TRVI in its 52-week range?
TRVI is trading at $14.05, which is 87% of its 52-week high ($16.12) and 81% above its 52-week low ($5.38).
How volatile is TRVI?
TRVI has a Beta of 1.06 and 52-week volatility of 62%. It's more volatile than the S&P 500 - expect bigger swings.